Previous 10 | Next 10 |
Gainers: MedAvail (MDVL) +72%. Lyra Therapeutics (LYRA) +31%. TSR (TSRI) +24%. Biofrontera (BFRI) +18%. Takung Art (TKAT) +16%. Akanda (AKAN) +15%. Mullen Automotive (MULN) +16%. Nurix Therapeutics (NRIX) +14%. Borr Drilling (BORR) +14%. EPAM Systems (EPAM) +13%. Losers: Kaleid...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re diving into the top penny stocks for today in our market update for Friday! Source: John Brueske/Shutterstock.com Before we get to the meat of this article, I’ve got to warn you about the potential...
The shares of Biofrontera (NASDAQ:BFRI) are trading higher for the second straight session on Friday to reach the highest level since January after the dermatology-focused biopharma company said its growth momentum returned in 2021. Chief Executive of Biofrontera (BFRI) Erica Monaco made the ...
Gainers: MedAvail MDVL +61%. Lyra Therapeutics LYRA +27%. Medicenna Therapeutics (MDNA) +25%. Biofrontera BFRI +23%. IsoPlexis (ISO) +8%. Losers: BioCryst Pharmaceuticals BCRX -33%. Sunshine Biopharma SBFM -33%. Werewolf Therapeutics (HOWL) -15%. I...
Buying Penny Stocks Today? What You Need to Know About Trading Penny Stocks With the end of another week of trading penny stocks and blue chips, there is a lot for investors to consider. While this week has been extremely volatile, today we are beginning to see signs of a bullish turnar...
Biofrontera (NASDAQ:BFRI) rose pre-market April 8 after it said that 2022 revenue is expected to increase by at least 30% compared to 2021. Q4 total revenue grew +6.95% Y/Y to $9.17M. Full year 2021 revenue rose by +27.86% to $24.1M. “Despite continued challenges resulting from the COV...
Biofrontera press release (NASDAQ:BFRI): Q4 GAAP EPS of -$1.29. Revenue of $9.17M (+7.0% Y/Y) Total revenues are expected to increase by at least 30% compared with 2021, including first quarter total revenues up by over 100% versus the first quarter prior year and typical seasonal strength in...
I ntroduces 2022 financial guidance Conference call begins at 11 :0 0 a .m. Eastern time today WOBURN, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”) , a biopharmaceutical ...
WOBURN, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today preliminary, unaudited product revenues for the quarter ended March 31, 2022. Pr...
WOBURN, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it will report financial results for the three months and full year ended December 31,...
News, Short Squeeze, Breakout and More Instantly...
The RhodoLED XL is approved by the FDA in combination with Ameluz ® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity on the face and scalp Biofrontera launched the commercial distribution of the Rhod...
Conference call begins at 10:00 a.m. Eastern time on Thursday, May 16, 2024 WOBURN, MA / ACCESSWIRE / May 15, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results f...
Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...